Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 2/20 | 0.49 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTR1D | P28221 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1683655 | 1.00 | HTR2B (0.49) | HTR2BGPR35DRD2DRD4DRD3 | |
| SCHEMBL723266 | 1.00 | HTR2B (0.49) | HTR2BGPR35DRD2DRD4DRD3 | |
| SCHEMBL14384029 | 0.86 | HTR2B (0.47) | HTR2BGPR35DRD2DRD4DRD3 | |
| SCHEMBL12872412 | 0.86 | GPR35 (0.56) | HTR2BGPR35MAPTTSHRALOX15 | |
| SCHEMBL10425856 | 0.86 | MAPT (0.52) | HTR2BGPR35MAPTTSHRALOX15 | |
| SCHEMBL9231796 | 0.86 | GPR35 (0.56) | HTR2BGPR35MAPTTSHRALOX15 | |
| SCHEMBL5494654 | 0.85 | GPR35 (0.45) | HTR2BGPR35MAPTTSHRALOX15 | |
| SCHEMBL5493591 | 0.85 | MAPT (0.46) | HTR2BGPR35MAPTTSHRALOX15 | |
| SCHEMBL31022773 | 0.84 | MKNK1 (0.46) | HTR2BGPR35 | |
| SCHEMBL12316835 | 0.84 | MKNK1 (0.46) | HTR2BGPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197388-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | EMPRESS THERAPEUTICS, INC. | 2025-06-19 | — | — | US | disclosed |
| CN-119487012-A | Compounds, pharmaceutical compositions and methods for treating inflammatory bowel disease | 旗舰创业创新六公司 | 2025-02-18 | — | — | CN | disclosed |
| EP-4499618-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | Flagship Pioneering Innovations VI, LLC (US) | 2025-02-05 | — | — | EP | disclosed |
| CN-110759873-B | 4, 5-dihydrothiazole carboxylic acid derivatives containing sulfonyl hydrazine structure, and preparation method and application thereof | 天津中医药大学 | 2023-12-19 | — | — | CN | disclosed |
| WO-2023192388-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023192388-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2023-10-05 | — | — | WO | disclosed |
| EP-3289876-B1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIV TENNESSEE RES FOUND (US) | 2022-07-20 | — | — | EP | disclosed |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Oncternal Therapeutics, Inc. (US) | 2022-01-27 | — | — | US | disclosed |
| US-11084811-B2 | Compounds for treatment of cancer | Oncternal Therapeutics, Inc. (US) | 2021-08-10 | — | — | US | disclosed |
| US-10865196-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2020-12-15 | — | — | US | disclosed |
| US-8592465-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-11-26 | — | — | US | disclosed |
| US-20120329842-A1 | SMALL MOLECULE COMPOUNDS AS BROAD-SPECTRUM INHIBITORS OF METALLO-BETA-LACTAMASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-12-27 | — | — | US | disclosed |
| US-20120329842-A1 | SMALL MOLECULE COMPOUNDS AS BROAD-SPECTRUM INHIBITORS OF METALLO-BETA-LACTAMASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-12-27 | — | — | US | disclosed |
| US-20120329842-A1 | SMALL MOLECULE COMPOUNDS AS BROAD-SPECTRUM INHIBITORS OF METALLO-BETA-LACTAMASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-12-27 | — | — | US | disclosed |
| WO-2012088283-A1 | SMALL MOLECULE COMPOUNDS AS BROAD-SPECTRUM INHIBITORS OF METALLO-BETA-LACTAMASES | BAYLOR COLLEGE OF MEDICINE (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012088283-A1 | SMALL MOLECULE COMPOUNDS AS BROAD-SPECTRUM INHIBITORS OF METALLO-BETA-LACTAMASES | BAYLOR COLLEGE OF MEDICINE (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2011-10-20 | — | — | US | disclosed |
| US-20090326020-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090326020-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2009-12-31 | — | — | US | disclosed |
| US-20080255213-A1 | THIAZOLIDINONE AMIDES, THIAZOLIDINE CARBOXYLIC ACID AMIDES, AND SERINE AMIDES, INCLUDING POLYAMINE CONJUGATES THEREOF, AS SELECTIVE ANTI-CANCER AGENTS | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326020-A1 | COMPOUNDS FOR TREATMENT OF CANCER | HCCS, NQO1, CCNY | HTR2B 1056/4885GPR35 1579/4885DRD2 2748/4885 |
| US-10865196-B2 | Compounds for treatment of cancer | CYP19A1, CYP17A1, SOX18 | HTR2B 3527/4885GPR35 2417/4885DRD2 4764/4885 |
| US-20080255213-A1 | THIAZOLIDINONE AMIDES, THIAZOLIDINE CARBOXYLIC ACID AMIDES, AND SERINE AMIDES, INCLUDING POLYAMINE CONJUGATES THEREOF, AS SELECTIVE ANTI-CANCER AGENTS | SRM, SAT1, SMS | HTR2B 3123/4885GPR35 2537/4885DRD2 2781/4885 |
| US-11084811-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | HTR2B 4622/4885GPR35 2364/4885DRD2 4550/4885 |
| US-20250197388-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | SI, VIP, APC | HTR2B 2431/4885GPR35 1704/4885DRD2 494/4885 |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | HTR2B 4622/4885GPR35 2364/4885DRD2 4550/4885 |
| US-20120329842-A1 | SMALL MOLECULE COMPOUNDS AS BROAD-SPECTRUM INHIBITORS OF METALLO-BETA-LACTAMASES | MGAM, MGAM2, BPGM | HTR2B 4716/4885GPR35 4365/4885DRD2 2313/4885 |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | HTR2B 4622/4885GPR35 2364/4885DRD2 4550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.